Business News

About Haisco

Hisicor is an international pharmaceutical company integrating research and development, production, and sales (stock code 002653.SZ). It focuses on areas such as anesthesia and analgesia, chronic disease metabolism, digestive liver diseases, respiratory autoimmune diseases, the nervous system, and tumors. Adhering to innovation and globalization strategies, with the vision of “becoming the most trusted international pharmaceutical company,” Hisicor aims to meet unmet clinical needs and care for patients worldwide. Currently, Hisicor Pharmaceutical Group has established a range of diversified research and development programs with independent intellectual property rights, covering small molecule innovative drugs, biopharmaceuticals, and high-end generic drugs. Many projects are in the clinical development stage, and several innovative drugs have been commercialized, providing diverse innovative product solutions to the world.

Statement

This information is intended to provide cutting-edge medical insights and research progress. It is for reference only by healthcare professionals, and is not intended for product promotion or advertising purposes. The content cannot replace professional medical guidance, and should not be considered as medical advice. Healthcare professionals should strictly follow the latest detailed prescribing information when prescribing any drugs mentioned in this document.

Some content may include forward-looking statements. These statements are based on the company’s current expectations for future developments and may be influenced by various uncertain factors such as research and development progress, regulatory approvals, and market conditions. For specific statements, please visit: https://www.haisco.com/statement.html.